Relevance of dyslipidaemia and its consequences in periodontal patients with co-existing cardiovascular disease and diabetes mellitus: Therapeutic targets

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 3, Issue 3, 2009, Pages 214-224

  Soory, Mena ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Dyslipidaemia; High density low density lipoproteins; Hyperglycaemia; Inflammation; Pathological mechanisms; Periodontal pathogens; Periodontology; Therapeutic targets

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; AMINOTHIOL; ANTIOXIDANT; ATORVASTATIN; DOXYCYCLINE; FLAVONOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1BETA; LACTOFERRIN; LIPOPOLYSACCHARIDE; LOW DENSITY LIPOPROTEIN; MELOXICAM; METFORMIN; METHYLCELLULOSE; METRONIDAZOLE; MINOCYCLINE; NICOTINIC ACID; PYCNOGENOL; PYRUVIC ACID; SIMVASTATIN; TETRACYCLINE DERIVATIVE; TOCOPHEROL; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UBIDECARENONE; VASCULAR CELL ADHESION MOLECULE 1;

ANTIBODY TITER; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROMA; ATHEROSCLEROSIS; BACTERIAL INFECTION; BACTERIAL STRAIN; BONE DEFECT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMORBIDITY; DENTAL PATIENT; DIABETES MELLITUS; DRUG FORMULATION; DRUG POTENTIATION; DRUG TARGETING; DYSLIPIDEMIA; ENDOTOXEMIA; GEL; HUMAN; HYPERLIPIDEMIA; IMMUNOMODULATION; INFLAMMATION; INNATE IMMUNITY; INSULIN RESISTANCE; LOW DRUG DOSE; MACROPHAGE; METABOLIC REGULATION; METABOLIC SYNDROME X; NEUROPROTECTION; OSSIFICATION; OSTEOLYSIS; OXIDATIVE STRESS; PATHOGENESIS; PERIODONTITIS; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SECONDARY PREVENTION;

EID: 70349199630     PISSN: 18722148     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221409789104700     Document Type: Review

References (106)

1. Grossi SG, Genco RJ. Periodontal disease and diabetes mellitus: A two way relationship. Ann Periodontol 1998; 3: 51-61.
2. Kurtis B, Develioglu H, Taner IL, Balos K, Tekin IO. IL-6 levels in gingival crevicular fluid (GCF) from patients with non-insulin dependent diabetes mellitus (NIDDM), adult periodontitis and healthy subjects. J Oral Sci 1999; 41: 163-167.
3. Janket SJ, Baird AE, Chuang SK, Jones JA. Meta-analysis of periodontal disease and risk of coronary heart disease and stroke (comment). Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003; 95: 559-569.
4. Janket SJ, Meurman JH, Nuutinen P, et al. Salivary lysozyme and prevalent coronary heart disease: Possible effects of oral health on endothelial dysfunction. Arterioscler Thromb Vasc Biol 2006; 26: 433-434.
5. Cherukuri, R.S.V., Cherukuri, R.C., Cherukuri, A., Natarajan, K.: US20060083700A1 (2006).
6. Choi J, Chung S, Kang H, Rhim B, Kim S, Kim S. Establishment of Porphyromonas gingivalis heat- shock- protein- specific T cell line from atherosclerosis patients. J Dent Res 2002; 81: 344-348.
7. Slade GD, Ghezzi EM, Heiss G, Beck JD, Riche E, Offenbacher S. Relationship between periodontal disease and C-reactive protein among adults in the atherosclerosis risk in Communities study. Arch Intern Med 2003; 163: 1172-1179.
8. Rahman ZA, Soory M. Antioxidant effects of glutathione and IGF in a hyperglycaemic cell culture model of fibroblasts: Some actions of advanced glycaemic end products (AGE) and nicotine. Endocr Metab Immune Disord - Drug Targets 2006; 6: 279-286.
9. Soory M. Periodontal disease severity and systemic diseases prevalent in a Caribbean catchment area of patients. West Indian Med J 2007; 56: 193-197.
10. Levy, A.: US20070218462A1 (2007).
11. Amar S, Gokce N, Morgan S, Loukideli M, Van Dyke TE, Vita JA. Periodontal disease is associated with brachial artery endothelial dysfunction and systemic inflammation (comment). Arterioscler Thromb Vasc Biol 2003; 23: 1245-1249.
12. Janket SJ, Jones JA, Meurman JH, Baird AE, Van Dyke TE. Oral infection, hyperglycaemia and endothelial dysfunction. Oral Surg Oral Med Oral Pathol Oral Radiol Endodont 2008; 105: 173-179.
13. Levy, A.P.: US20036613519 (2003).
14. Lalla E, Lamster IB, Feit M, et al. Blockade of RAGE suppresses periodontitis-associated bone loss in diabetic mice. J Clin Invest 2000; 105:1117-1124.
15. D'Aiuto F, Parkar M, Nibali L, Suvan J, Lessem J, Tonetti MS. Periodontal infections cause changes in traditional and novel cardiovascular risk factors: Results from a randomized controlled clinical trial. Am Heart J 2006; 151: 977-984.
16. Elter JR, Hinderliter Al, Offenbacher S, et al. The effects of periodontal therapy on vascular endothelial function: A pilot trial. Am Heart J 2006; 151: 47 e41-47
17. Iwamoto Y, Nishimura F, Soga Y, et al. Antimicrobial periodontal treatment decreases serum C-reactive protein, tumour necrosis factor-alpha but not adiponectin levels in patients with chronic periodontitis. J Periodontol 2003; 74:1231-1236.
18. Tonetti MS, D'Aiuto F, Nibali L, et al. Treatment of periodontitis and endothelial function. N Engl J Med 2007; 356: 911-920.
19. Offenbacher S, Beck JD, Moss K, et al. Results from the Periodontitis and Vascular Events (PAVE) Study: A pilot multicentered, randomized, controlled trial to study effects of periodontal therapy in a secondary prevention model of cardiovascular disease. J Periodontol 2009; 80:190-201.
20. Svensson, M., Christensen, J.H., Schmidt, E.B., Jorgensen, K.A.: US20080125490A1 (2008).
21. Boddupalli, S., Miller, G., Wang, B.: US20040097433A1 (2004).
22. Vanuzzo D, Pilotto L, Mirolo R, Pirelli S. Cardiovascular risk and cardiometabolic risk: An epidemiological evaluation. G Ital Cardiol (Rome) 2008; 9 (Suppl 1):6S-17S
23. Sosnowski, R.E., Lang, P.C.: US20040087479A1 (2004).
24. Sattar N, McConnachie A, Shaper AG, et al. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet 2008; 371:1927-1935.
25. Krolewski, A.S., Pezzolesi, M.G., Nagase, T.: US20080227737A1 (2008).
26. Parikh P, Mochari H, Mosca L. Clinical utility of a fingerstick technology to identify individuals with abnormal blood lipids and high-sensitivity C-reactive protein levels. Am J Health Promot 2009; 23: 279-282.
27. Wong, N.C.W., Tucker, J.E.L., Hansen, H.C., Chiacchia, F.S., McCaffrey, D.: US20060205792A1 (2006).
28. Yu R, Kim CS, Kang JH. Inflammatory components of adipose tissue as target for treatment of metabolic syndrome. Forum Nutr 2009; 61: 95-103.
29. Blatt, L.M., Seiwert, S.D., Beigelman, L., Radhakrishnan, R.: US20060270612A1 (2006).
30. Allam, A.R., Gumpeny, S., Das, U.: US20080187944A1 (2008).
31. Goteiner D, Craig RG, Ashmen R, Janal MN, Eskin B, Lehrman N. Endotoxin levels are associated with high-density lipoprotein, triglycerides and troponin in patients with acute coronary syndrome and angina: Possible contributions from periodontal sources. J Periodontol 2008; 79: 2331-2339.
32. Wong, N.C.W., Tucker, J.E.L., Hansen, H.C., Chiacchia, F.S., Mccaffrey, D.: US20080188467A1 (2008).
33. Kallio KA, Buhlin K, Jauhiainen M, et al. Lipopolysaccharide associates with pro-atherogenic lipoproteins in periodontitis patients. Innate Immun 2008; 14: 247-253.
34. Bennett-Guerrero, E., Barclay, G.R., Poxton, I.R., Mcintosh, T.J., Snyder, D.S.: US20046749831 (2004).
35. Nishimura F, Taniguchi A, Yamaguchi-Morimoto M, et al. Periodontal infection and dyslipidemia in type 2 diabetics: Association with increased HMG-CoA reductase expression. Horm Metab Res 2006; 38: 530-535.
36. Heinecke, J.W., Vaisar, T.: US20070099242A1 (2007).
37. Lakio L, Lehto M, Tuomainen AM, et al. Pro-atherogenic properties of lipopolysaccharide from the periodontal pathogen Actinobacillus actinomycetemcomitans. J Endotoxin Res 2006; 12: 57-64.
38. Wong, N.C.W., Tucker, J.E.L., Hansen, H.C., Chiacchia, F.S., McCaffrey, D.: US20060205767 (2006).
39. Kuramitsu HK, Miyakawa H, Qi M, Kang IC. Cellular responses to oral pathogens. Ann Periodontol 2002; 7: 90-94.
40. Medford, R.M., Alexander, W.R., Parthasarathy, S., Khan, B.V.: US5750351 (1998).
41. Zeiher, A.M., Heeschen, C., Dimmeler, S., Hamm, C.: US20070042438A1 ( 2007).
42. Pussinen PJ, Mattila K. Periodontal infections and atherosclerosis: Mere associations? Curr Opin Lipidol 2004; 15: 583-588.
43. Dev, I.K., Subbiah, V.: US20070208079A1 (2007).
44. Oörni K, Kovanen PT. Proteolysis of low density lipoprotein particles by Porphyromonas gingivalis microorganisms: A novel biochemical link between periodontitis and cardiovascular diseases? J Intern Med 2008; 263: 553-557.
45. Qi M, Miyakawa H, Kuramitsu HK. Porphyromonas gingivalis induces murine macrophage foam cell formation. Microb Pathog 2003; 35: 259-267.
46. Heinecke, J.W., Oram, J.F.: US20080261250A1 (2008).
47. Kuramitsu HK, Kang IC, Qi M. Interactions of Porphyromonas gingivalis with host cells: Implications for cardiovascular diseases. J Periodontol 2003; 74: 85-89
48. Jia, Q., Farrow, T.M.: US20056884783 (2005).
49. Kuramitsu HK, Qi M, Kang IC, Chen W. Role for periodontal bacteria in cardiovascular diseases. Ann Periodontol 2001; 6: 41-47.
50. Prasad, K.: US20026486126 (2002).
51. Hajishengallis G, Sharma A, Russell MW, Genco RJ. Interactions of oral pathogens with toll-like receptors: Possible role in atherosclerosis. Ann Periodontol 2002; 7: 72-78.
52. Johnson, R.S., Guo, L., Peschon, J.J., Black, R.A., Mahimkar, R.M.: US20030108959A1 (2003).
53. Reismann P, Rácz K, Tulassay Z. Polymorphism of the Toll-like receptor 4 gene and their potential role in infectious diseases and chronic inflammatory disorders. Orv Hetil 2008;149:1791-1799.
54. Chan, B.P., Po, W., Gary, K., Xu, J., Chi, F.: US20050137125 (2005).
55. Saxena, U., Pillarisetti, S., Khanna, I.: US20080214531A1 (2008).
56. Madan M, Amar S. Toll-like receptor-2 mediates diet and/or pathogen associated atherosclerosis: Proteomic findings. PloS One 2008; 3: e3204.
57. Hendrix, C.: US20080214492A1 (2008).
58. Gibson FC 3rd, Genco CA. Porphyromonas gingivalis mediated periodontal disease and atherosclerosis: Disparate diseases with commonalities in pathogenesis through TLRs. Curr Pharm Des 2007; 13: 3665-3675.
59. Gibson FC 3rd, Ukai T, Genco CA. Engagement of specific innate immune signalling pathways during Porphyromonas gingivalis, induced chronic inflammation and atherosclerosis. Front Biosci 2008; 13: 2041-2059.
60. Ebersole JL, Cappelli D, Mott G, Kesavalu L, Holt SC, Singer RE. Systemic manifestations of periodontitis in the non-human primate. J Periodontal Res 1999; 34: 358-362.
61. Petyaev, I.: US20067148028 (2006).
62. Rongen, R.M.L., Bobotas, G., Bodd, E., Vik, H.: US20090012167 (2009).
63. Mattila KJ, Pussinen PJ, Paju S. Dental infections and cardiovascular diseases: A review. J Periodontol 2005; 76 (Suppl 11): 2085-2088.
64. Salonen, J.: US20050064497A1 (2005).
65. Garvey, D.S., Letts, G.L., Worcel, M.: US20070238740A1 (2007).
66. Pussinen PJ, Tuomisto K, Jousilahti P, Havulinna AS, Sundvall J, Salomaa V. Endotoxemia, immune response to periodontal pathogens and systemic inflammation associate with incident cardiovascular events. Arterioscler Thromb Vasc Biol 2007; 27: 1433-1439.
67. Pussinen PJ, Vilkuna-Rautiainen T, Alfthan G, et al. Severe periodontitis enhances macrophage activation via increased serum lipopolysaccharide. Arterioscler Thromb Vasc Biol 2004; 24: 2174-2180.
68. Pussinen PJ, Paju S, Mäntylä P, Sorsa T. Serum microbial- and host-derived markers of periodontal diseases: A review. Curr Med Chem 2007; 14: 2402-2412.
69. Malfroy-Camine, B., Doctrow, S.R.: US5696109 (1997).
70. Mustapha IZ, Debrey S, Oladubu M, Ugarte R. Markers of systemic bacterial exposure in periodontal disease and cardiovascular disease risk: A systemic review and meta-analysis. J Periodontol 2007; 78: 2289-2302.
71. Beinlich, P., Boddupalli, S., Brown, L.A., Dreon, D.M., Flaim, S., Miller, G., Phinney, S.D.: US20067081476 (2006).
72. Beinlich, P., Boddupalli, S., Brown, L.A., Dreon, D.M., Flaim, S., Miller, G., Phinney, S.D.: US20030100603A1 (2003).
73. Miller, G., Brown, L.A.: US20030022818A1 (2003).
74. Sakoda K, Yamamoto M, Negishi Y, Liao JK, Node K, Izumi Y. Simvastatin decreases IL-6 and IL-8 production in epithelial cells. J Dent Res 2006; 85: 520-523.
75. Pandian A, Arora A, Sperling LS, Khan BV. Targeting multiple dyslipidemias with fixed combinations-focus on extended release niacin and simvastatin. Vasc Health Risk Manag 2008; 4: 1001-1009.
76. Sundararaj KP, Samuvel DJ, Li Y, et al. Simvastatin suppresses LPS-induced MMP-1 expression in U 937 mononuclear cells by inhibiting protein isoprenylation-mediated ERK activation. J Leukocyte Biol 2008; 84: 1120-1129.
77. Vaziri H, Naberhojjati-Roodsari R, Tahsili-Fahdan N, et al. Effect of simvastatin administration on periodontitis-associated bone loss in ovariectomised rats. J Periodontol 2007; 78:1561-1567.
78. Morris MS, Lee Y, Lavin MT, et al. Injectable simvastatin in periodontal defects and alveolar ridges: Pilot studies. J Periodontol 2008; 79: 1465-1473.
79. Seto H, Ohba H, Tokunaga K, Hama H, Horibe M, Nagata T. Topical administration of simvastatin recovers alveolar bone loss in rats. J Periodontal Res 2008; 43: 261-267.
80. Lindy O, Suomalainen K, Mäkelä M, Lindy S. Statin use is associated with fewer periodontal lesions: A retrospective study. BMC Oral Health 2008; 8: 16.
81. Nareika A, Maldonado A, He L, et al. High glucose boosted inflammatory responses to lipopolysaccharide are suppressed by statin. J Periodontal Res 2007; 42: 31-38.
82. Aldini, G., Yeum, K.-J.:US20020182736 (2002).
83. Ott C, Schmieder RE. The role of statins in the treatment of the metabolic syndrome. Curr Hypertens Rep 2009; 11:143-149.
84. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004; 109: lll-39-lll-43.
85. Liao JK, Laufs U. Pleiotropic effects of statins. Ann Rev Pharmacol Toxicol 2005; 45: 89-118.
86. Babish, J.G.:US20030054978A1 (2003).
87. Takebayashi K, Matsumoto S, Wakabayashi S, et al. The effect of low dose atorvastatin on circulating monocyte chemoattractant protein-1 in patients with type 2 diabetes complicated by hyperlipidaemia. Metabolism 2005; 54:1225-1229.
88. Arca M. Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome. Drugs 2007; 67 (Suppl 1): 43-54.
89. Stroes, E.S.G.: US20080214434A1 (2008).
90. Roberts CK, Sindhu KK. Oxidative stress and metabolic syndrome. Life Sci 2009; 84(21-22): 705-12.
91. Finley, J.W., Mezine, I., Finley, J.W., Gao, S., Hoyt, I., Opet, M.M., Zhang, H.: US20060172012A1 (2006).
92. Kosbab, J.V.: US20010031744A1 (2001).
93. Amar S, Wu SC, Madan M. Is Porphyromonas gingivalis cell invasion required for atherogenesis? Pharmacotherapeutic implications. J Immunol 2009; 182:1584-1592.
94. Madan M, Bishayi B, Hoge M, Messas E, Amar S. Doxycycline affects diet- and bacteria-associated atherosclerosis in an ApoE heterozygote murine model: Cytokine profiling implications. Atherosclerosis 2007; 190: 62-72.
95. Flodgaard, H., Rasmussen, P.B.: US5939390 (1999).
96. Figuero E, Soory M, Cerero R, Bascones A. Oxidant/antioxidant interactions of nicotine, Coenzyme Q10, Pycnogenol and phytoestrogens in oral periosteal fibroblasts and MG63 osteoblasts. Steroids 2006; 71: 1062-1072.
97. Soory M. Redox status in periodontal and systemic inflammatory conditions including associated neoplasias: Antioxidants as adjunctive therapy? Infect Disord 2009; (In press).
98. Lockwood, S.F.: US20070238793A1 (2007).
99. Soory M. Relevance of nutritional antioxidants in metabolic syndrome, ageing and cancer: Potential for therapeutic targeting. Infect Disord 2009; (In press).
100. Soory M. A role for non-antimicrobial actions of tetracyclines in combating oxidative stress in periodontal and metabolic diseases. The Open Dent J 2008; 2: 5-12.
101. Ryu JK, Choi HB, McLarnon JG. Combined minocycline plus pyruvate treatment enhances effects of each agent to inhibit inflammation, oxidative damage and neuronal loss in an excitotoxic animal model of Huntington's disease. Neuroscience 2006; 141: 835-848.
102. Nelson, M.L., Frechette, R., Viski, P., Ismail, M., Bowser, T., Dumornay, J., Rennie, G., Liu, G., Koza, D., Sheahan, P., Stapleton, K., Hawkins, P., Bhatia, B., Verma, A.K., Mcintyre, L., Warchol, T., Messersmith, D.: US20040214801 (2004).
103. Wang JY, Wen LL, Huang YN, Chen YT, Ku MC. Dual effects of antioxidants in neurodegeneration: Direct neuroprotection against oxidative stress and indirect protection via suppression of gliamediated inflammation. Curr Pharm Des 2006; 12: 3521-3533.
104. Henderson, T.R., Frondoza, C.: US20070141181A1 (2007).
105. Melero-Fernández de Mera RM, García-Martínez E, Fernández-Gómez FJ, et al. Is good old minocycline a new neuroprotective drug? Rev Neurol 2008; 47: 31-38.
106. Jordan J, Fernandez-Gomez FJ, Ramos M, Ikuta I, Aguirre N, Galindo MF. Minocycline and cytoprotection: Shedding new light on a shadowy controversy. Curr Drug Deliv 2007; 4: 225-231.